About Us
DemeRx-NB is advancing noribogaine in clinical trials to demonstrate its use as a safe and effective treatment for alcohol use disorder.
Alcohol and drug abuse “hijacks” the brain’s reward centers. Painful cravings during early withdrawal drive an intractable cycle of relapse.
Open label studies of ibogaine has demonstrated benefits in patients seeking to transition to sobriety. Recent studies demonstrate that drug turns on neuroplasticity in addiction circuits of the brain. These changes bring about a rapid “reset” which shuts off the blaring cravings and desire to use alcohol and drugs.
Noribogaine is an active metabolite of ibogaine and a potent neuroplastogen without the side effects of ibogaine.
DemeRx plans to develop a daily dose formulation of DMX-1001 (noribogaine) for the treatment of alcohol use disorder.
![](https://www.demerx.com/wp-content/uploads/2022/12/vector.png)
Bridging the research to clinical practice gap
Our Goal
We plan to advance oral dose formulations of noribogaine for patients in early recovery from alcohol use disorder to prevent relapse.
Result Driven
DemeRx will design clinical trials to demonstrate that noribogaine provides a fast and lasting effect on alcohol craving, maintenance of abstinence or avoidance of heavy drinking in moderate to severe alcoholic patients who have sought treatment and successfully completed acute withdrawal.
![](https://www.demerx.com/wp-content/uploads/2022/09/relief.jpg)
Key Team
![](https://www.demerx.com/wp-content/uploads/2022/12/Deborah-Mash.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Richard-Serbin.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Richard-Serbin.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Richard-Serbin.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Michael.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Michael.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/pascal.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/pascal.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/pascal.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/John.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/John.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/John.jpg)
Key Team
![](https://www.demerx.com/wp-content/uploads/2022/12/Richard-Serbin.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Richard-Serbin.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Richard-Serbin.jpg)
Richard Serbin, Executive Chairman BoD
![](https://www.demerx.com/wp-content/uploads/2022/12/Deborah-Mash.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Deborah-Mash.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/Deborah-Mash.jpg)
Deborah Mash, PhD Chief Executive Officer & Founder
![](https://www.demerx.com/wp-content/uploads/2024/07/Mark-Ellison-CIM2.png)
![](https://www.demerx.com/wp-content/uploads/2024/07/Mark-Ellison-CIM2.png)
Mark Ellison, PhD
![](https://www.demerx.com/wp-content/uploads/2022/12/pascal.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/pascal.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/pascal.jpg)
Pascal J. Goldschmidt MD, FACC, FAHA, Chief Medical Officer
![](https://www.demerx.com/wp-content/uploads/2022/12/John.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/John.jpg)
![](https://www.demerx.com/wp-content/uploads/2022/12/John.jpg)